Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD44v9 antibody-drug conjugate AMT-116

An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) CD44 variant 9 (CD44v9), linked to the topoisomerase I inhibitor (TOP1i) and belotecan derivative KL610023 via a hydrolysable linker, with potential antineoplastic activity. Upon intravenous administration of anti-CD44v9 ADC AMT-116, the monoclonal antibody moiety targets and binds to CD44v9 expressed on tumor cells. Upon binding and internalization, KL610023 is released. KL610023 targets and binds to DNA topoisomerase I, thereby inhibiting DNA replication and killing the CD44v9-expressing cancer cells. CD44v9, a splicing variant of CD44 overexpressed in numerous cancer cell types, is associated with tumorigenicity and cancer treatment resistance.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC AMT-116
anti-CD44v9 ADC AMT-116
Code name:AMT 116
AMT-116
AMT116
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search